196 related articles for article (PubMed ID: 32338990)
1. Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis.
Morizumi S; Sato S; Koyama K; Okazaki H; Chen Y; Goto H; Kagawa K; Ogawa H; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Am J Respir Cell Mol Biol; 2020 Sep; 63(3):317-326. PubMed ID: 32338990
[TBL] [Abstract][Full Text] [Related]
2. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
3. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.
MacKenzie B; Korfei M; Henneke I; Sibinska Z; Tian X; Hezel S; Dilai S; Wasnick R; Schneider B; Wilhelm J; El Agha E; Klepetko W; Seeger W; Schermuly R; Günther A; Bellusci S
Respir Res; 2015 Jul; 16(1):83. PubMed ID: 26138239
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
5. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
6. Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation.
Tian Y; Li H; Qiu T; Dai J; Zhang Y; Chen J; Cai H
Aging Cell; 2019 Feb; 18(1):e12858. PubMed ID: 30548445
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 Is Required for AEC2 Homeostasis and Survival after Bleomycin-induced Lung Injury.
Dorry SJ; Ansbro BO; Ornitz DM; Mutlu GM; Guzy RD
Am J Respir Cell Mol Biol; 2020 May; 62(5):608-621. PubMed ID: 31860803
[TBL] [Abstract][Full Text] [Related]
8. Emodin ameliorates bleomycin-induced pulmonary fibrosis in rats by suppressing epithelial-mesenchymal transition and fibroblast activation.
Guan R; Wang X; Zhao X; Song N; Zhu J; Wang J; Wang J; Xia C; Chen Y; Zhu D; Shen L
Sci Rep; 2016 Oct; 6():35696. PubMed ID: 27774992
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling.
Guzy RD; Li L; Smith C; Dorry SJ; Koo HY; Chen L; Ornitz DM
J Biol Chem; 2017 Jun; 292(25):10364-10378. PubMed ID: 28487375
[TBL] [Abstract][Full Text] [Related]
11. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
13. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis.
Shimbori C; Bellaye PS; Xia J; Gauldie J; Ask K; Ramos C; Becerril C; Pardo A; Selman M; Kolb M
J Pathol; 2016 Oct; 240(2):197-210. PubMed ID: 27425145
[TBL] [Abstract][Full Text] [Related]
15. Neurotrophic tyrosine kinase receptor B/neurotrophin 4 signaling axis is perturbed in clinical and experimental pulmonary fibrosis.
Avcuoglu S; Wygrecka M; Marsh LM; Günther A; Seeger W; Weissmann N; Fink L; Morty RE; Kwapiszewska G
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):768-80. PubMed ID: 21330466
[TBL] [Abstract][Full Text] [Related]
16. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
18. Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways.
Chen B; Cai HR; Xue S; You WJ; Liu B; Jiang HD
Respirology; 2016 Aug; 21(6):1075-80. PubMed ID: 27185272
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.
Guzy RD; Stoilov I; Elton TJ; Mecham RP; Ornitz DM
Am J Respir Cell Mol Biol; 2015 Jan; 52(1):116-28. PubMed ID: 24988442
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
